QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNYSE:QGEN
CUSIPN/A
Phone31-77-355-6600
Debt
Debt-to-Equity Ratio0.52
Current Ratio2.14
Quick Ratio1.94
Price-To-Earnings
Trailing P/E Ratio28.69
Forward P/E Ratio27.19
P/E Growth2.29
Sales & Book Value
Annual Sales$1.42 billion
Price / Sales5.87
Cash Flow$2.3293 per share
Price / Cash15.64
Book Value$11.13 per share
Price / Book3.27
Profitability
EPS (Most Recent Fiscal Year)$1.27
Net Income$40.39 million
Net Margins3.79%
Return on Equity11.91%
Return on Assets6.13%
Miscellaneous
Employees4,688
Outstanding Shares228,230,000
Qiagen (NYSE:QGEN) Frequently Asked Questions
What is Qiagen's stock symbol?
Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."
How were Qiagen's earnings last quarter?
Qiagen NV (NYSE:QGEN) released its quarterly earnings data on Wednesday, May, 2nd. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.24 by $0.02. The company had revenue of $343.57 million for the quarter, compared to the consensus estimate of $340.10 million. Qiagen had a return on equity of 11.91% and a net margin of 3.79%. View Qiagen's Earnings History.
What price target have analysts set for QGEN?
7 Wall Street analysts have issued twelve-month price targets for Qiagen's stock. Their predictions range from $37.00 to $40.00. On average, they anticipate Qiagen's stock price to reach $38.50 in the next year. View Analyst Ratings for Qiagen.
Who are some of Qiagen's key competitors?
Some companies that are related to Qiagen include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Crispr Therapeutics (CRSP), argenx (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA) and Repligen (RGEN).
Who are Qiagen's key executives?
Qiagen's management team includes the folowing people:
- Mr. Peer Michael Schatz, CEO, MD & Member of Management Board (Age 52)
- Dr. Roland Sackers, CFO, MD & Member of Management Board (Age 49)
- Mr. Mark Gladwell, Sr. VP of Global Operations (Age 43)
- Mr. John Gilardi, VP of Corp. Communications & Investor Relations
- Mr. Jean-Pascal Viola, Head of Corp. Bus. Devel. & Intellectual Property & Litigation and Sr. VP
Has Qiagen been receiving favorable news coverage?
News coverage about QGEN stock has been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Qiagen earned a news sentiment score of 0.09 on Accern's scale. They also assigned news articles about the company an impact score of 46.40 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Qiagen?
Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Qiagen's stock price today?
One share of QGEN stock can currently be purchased for approximately $36.43.
How big of a company is Qiagen?
Qiagen has a market capitalization of $8.39 billion and generates $1.42 billion in revenue each year. The company earns $40.39 million in net income (profit) each year or $1.27 on an earnings per share basis. Qiagen employs 4,688 workers across the globe.
How can I contact Qiagen?
Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912 PL. The company can be reached via phone at 31-77-355-6600 or via email at [email protected]
MarketBeat Community Rating for Qiagen (QGEN)
MarketBeat's community ratings are surveys of what our community members think about Qiagen and other stocks. Vote "Outperform" if you believe QGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
